“BPC-157 and similar peptides are safe and help injuries heal.”
BPC-157 has barely been tested in people, so no one knows whether it is safe or helps injuries heal.
Promising animal results and online success stories are not proof that BPC-157 is safe or works in people. Using it now means taking on unknown risks for an unproven benefit.
Get the injury checked and follow a rehab plan made for that injury. Do not inject a research peptide based on testimonials or animal studies.
Safety note: BPC-157 is not part of any approved medicine in the United States or any other country. Products sold online or by clinics raise concerns about purity, dose and contamination, and FDA warns that injected peptides can trigger immune reactions. In animal tests reviewed by FDA, 28 days of injections showed possible effects on blood clotting and the liver. BPC-157 is banned at all times in sport under the World Anti-Doping Agency list.
Talk to a healthcare professional if: you have an injury that is not healing as expected, or you are thinking about using BPC-157 or another experimental peptide.
Animal studies suggest BPC-157 may help injured tissue heal. A 2026 review found only three small human studies, with 30 people in total and no comparison groups, and rated the certainty of the evidence very low, so it is too early to say whether it works or is safe in people.
BPC-157 has barely been tested in people, so no one knows whether it is safe or helps injuries heal. Most of the healing evidence comes from animal studies, and the few human studies were tiny, had no comparison group and mostly measured pain. For a similar peptide, TB-500, FDA found no published studies in people at all.
A 2026 review of all human studies found three: knee-pain injections in 16 people, a bladder condition in 12 people, and an IV safety test in 2 people. All three came from clinics in one city and shared the same lead author, who founded a group that opposes peptide regulation. The review judged all three to be poor quality. An earlier 2025 review found 35 animal or lab studies and only one human study.
As of April 2026, BPC-157 is no longer on FDA's list of compounding ingredients that may pose significant safety risks. It came off because the people who nominated it withdrew their nominations, not because FDA found it safe, and FDA's page still says it lacks enough safety information to know whether it causes harm. In July 2026, an FDA advisory committee voted 8 to 6, with 1 abstaining, to recommend letting pharmacies compound it for ulcerative colitis. FDA staff had advised against this, finding a lack of evidence that it works for that condition. The vote does not bind FDA and is not drug approval.
- Poolton JT, Minett J, Kazmi A. Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safety. Acta Orthopaedica Belgica. 2026;92(3). DOI: 10.52628/92.3.15837. PMID: 42885452
- Vasireddi N, Hahamyan H, Salata MJ, Karns M, Calcei JG, Voos JE, Apostolakos JM. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal. 2025;21(4):485-495. DOI: 10.1177/15563316251355551. PMID: 40756949. PMCID: PMC12313605
- U.S. Food and Drug Administration. FDA presentations to the Pharmacy Compounding Advisory Committee, July 23, 2026: BPC-157, KPV, TB-500 and MOTS-c related bulk drug substances. FDA document 193773
- U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Content current as of 04/22/2026
- Moeller M. FDA Advisory Committee Recommends Adding Six of Seven Peptides to Compounding List. American Med Spa Association. July 24, 2026